▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3084 by analyst upside · 2026-09-29
BNTX
BioNTech SE
Healthcare · Market Cap $25B · P/E 0x
ANALYST PRICE TARGET
+18.2%
implied upside to consensus target
Current Price $99.08
Consensus Target $117.13
Bull Target $141.33
Bear Target $74.08
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
13
Hold
5
Sell
1
52-Week Low $79.52
52-Week High $124.0
YTD Return +2.5%
FUNDAMENTALS
Market Cap $25B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.68
PEG Ratio 0.05
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin -63.6%
52-WEEK RANGE
52-Week Low $79.52
52-Week High $124.0
Current Price $99.08
Bear Target $74.08
Bull Target $141.33
● Now $99.08 ● Target $117.13
TRADING DATA
Avg Volume 1.1M
YTD Return +2.5%
Analyst Count 20
Consensus Buy
Upside to Target +18.2%
Last Updated 2026-09-29

ANALYST SUMMARY

BioNTech SE (BNTX) is currently trading at $99.08 with a Wall Street consensus price target of $117.13, implying potential upside of 18.2% over the next 12 months. 20 analysts currently cover BNTX, with a consensus rating of Buy - 70% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $141.33, while the most cautious has a target of $74.08.

BNTX operates in the Healthcare sector with a market capitalisation of $25B. The stock is up 2.5% year-to-date and is currently trading near the lower end of its 52-week range of $79.52 – $124.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BNTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BMO Capital ↓ Downgrade
Outperform → Market Perform 2026-09-08 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-31 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-05 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-08-05 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-08 Building track record
UBS ↑ Upgrade
Neutral → Buy 2026-05-27 33% win rate (6 calls)
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
23/30
Consensus clarity
16/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →